StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63+0.00 (+0.13%)

Close on Nov 18, 2026Market cap $23.87MP/E –Yield –

Metagenomi Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Metagenomi Therapeutics's revenue for the twelve months ending Mar 31, 2026 was $22.33M, down 50.7% year over year. For fiscal 2025 it was $25.21M, down 51.8% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$25.21M-51.8%
FY2024Dec 31, 2024$52.30M+16.8%
FY2023Dec 31, 2023$44.76M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$1.25M-69.8%
Q4 FY2025Dec 31, 2025$3.91M-59.3%
Q3 FY2025Sep 30, 2025$8.66M-24.8%
Q2 FY2025Jun 30, 2025$8.51M-57.5%
Q1 FY2025Mar 31, 2025$4.13M-63.0%
Q4 FY2024Dec 31, 2024$9.61M-22.5%
Q3 FY2024Sep 30, 2024$11.51M-6.9%
Q2 FY2024Jun 30, 2024$20.01M+76.5%
Q1 FY2024Mar 31, 2024$11.16M+28.9%
Q4 FY2023Dec 31, 2023$12.40M–
Q3 FY2023Sep 30, 2023$12.36M–
Q2 FY2023Jun 30, 2023$11.34M–
Q1 FY2023Mar 31, 2023$8.66M–

More Metagenomi Therapeutics figures

See a number that looks wrong?